The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

Objective To determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes. Design Retrospective cohort study using a nested case-control analysis. Setting Over 600 general practices in the United Kingdom contributing to the general practice research database. Participants The cohort consisted of people with type 2 diabetes who were newly treated with oral hypoglycaemic agents between 1 January 1988 and 31 December 2009. All incident cases of bladder cancer occurring during follow-up were identified and matched to up to 20 controls on year of birth, year of cohort entry, sex, and duration of follow-up. Exposure was defined as ever use of pioglitazone, along with measures of duration and cumulative dosage. Main outcome measure Risk of incident bladder cancer associated with use of pioglitazone. Results The cohort included 115 727 new users of oral hypoglycaemic agents, with 470 patients diagnosed as having bladder cancer during follow-up (rate 89.4 per 100 000 person years). The 376 cases of bladder cancer that were diagnosed beyond one year of follow-up were matched to 6699 controls. Overall, ever use of pioglitazone was associated with an increased rate of bladder cancer (rate ratio 1.83, 95% confidence interval 1.10 to 3.05). The rate increased as a function of duration of use, with the highest rate observed in patients exposed for more than 24 months (1.99, 1.14 to 3.45) and in those with a cumulative dosage greater than 28 000 mg (2.54, 1.05 to 6.14). Conclusion The use of pioglitazone is associated with an increased risk of incident bladder cancer among people with type 2 diabetes.

[1]  R. Breyer,et al.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. , 1999, Neoplasia.

[2]  G M Leydon,et al.  Validation of the diagnosis of venous thromboembolism in general practice database studies. , 2000, British journal of clinical pharmacology.

[3]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[4]  L. G. García Rodríguez,et al.  Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.

[5]  H Jick,et al.  Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. , 1991, BMJ.

[6]  R. Lawrenson,et al.  Clinical information for research; the use of general practice databases. , 1999, Journal of public health medicine.

[7]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[8]  Y. Kawahito,et al.  Expression of peroxisome proliferator‐activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists , 2003, International journal of cancer.

[9]  S. Larsson,et al.  Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.

[10]  M. L. Bruin,et al.  Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data , 2012, Diabetologia.

[11]  H. Kandori,et al.  Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. , 2011, Toxicology and applied pharmacology.

[12]  W. Bilker,et al.  Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.

[13]  S. Benoit,et al.  Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study , 2005, BMC public health.

[14]  K. Hattori,et al.  Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. , 2001, The American journal of pathology.

[15]  Elisabetta Poluzzi,et al.  Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.

[16]  Samy Suissa,et al.  The nested case-control study in cardiology. , 2003, American heart journal.

[17]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[18]  S. Suissa.  Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis , 2002 .

[19]  E. Oetjen.  Antidiabetic actions of a non–agonist PPARγ ligand blocking Cdk5–mediated phosphorylation , 2012 .

[20]  E. Wilkinson.  Cancer Research UK , 2002 .

[21]  B. Kahn,et al.  Rosiglitazone, PPARγ, and type 2 diabetes. , 2010, The New England journal of medicine.

[22]  Michal Abrahamowicz,et al.  Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure , 2005 .

[23]  M. Cano,et al.  Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. , 2006, Toxicologic pathology.

[24]  Corri Black,et al.  Validity of the General Practice Research Database , 2003, Pharmacotherapy.

[25]  E. Ward,et al.  Royal Colleges must act over Health and Social Care Bill , 2011, The Lancet.

[26]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[27]  Samuel M. Cohen,et al.  Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  M. Lai,et al.  Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus , 2012, Hepatology.

[29]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[30]  A. Ferrara,et al.  Diabetes and risk of bladder cancer , 2011, Cancer.

[31]  Scott A. Busby,et al.  Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation , 2011, Nature.

[32]  R. Breyer,et al.  Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death , 1999 .

[33]  Samuel M. Cohen,et al.  Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action , 2006, Toxicologic pathology.

[34]  R. Perera,et al.  Adaptation and validation of the Charlson Index for Read/OXMIS coded databases , 2010, BMC family practice.

[35]  Krystal L. Edwards,et al.  Third‐Line Agent Selection for Patients with Type 2 Diabetes Mellitus Uncontrolled with Sulfonylureas and Metformin , 2008, Pharmacotherapy.